When penicillin was discovered in 1928 by Alexander Fleming no one knew quite how great of an impact this drug would make on the world. The actual use of penicillin to treat infection did not begin until the mid-1940s, when a powdery form of this medication was developed by Howard Florey and Ernst Chain. The actual patent for Penicillin was granted to scientist Andrew J. Moyer was in 1948, which led to the mass production of this lifesaving discovery. However, with the advent of this treatment for infections, ranging from upper respiratory infections to ear infections, resistance began to become a concern. The appearance of resistant microbes starting showing up soon after the full scale production of penicillin, and the situation continued to get increasingly dire. The first resistant bacterium to become of serious concern to penicillin was the Staphylococcus aureus “bug”.
Fast forward eighty five years and enter the age of modern medicine. While the evolution of effectual and targeted treatments for both generalized and specific infections has continued to grow, we are still in need of medications that are not resistant. The ability of scientists to develop a drug to treat the infamous “superbug” has yet to be created.
In fact, a report released on April 18, 2013 by the Infectious Diseases Society of America, also known as the IDSA, offered a sobering picture of antibiotic resistant drugs. The report found that seven of the current drugs known to be in development have not been shown to address the full spectrum of resistance to gram-negative bacilli, or GNB bacteria. GNB includes infections such as E. coli, Shigella, salmonella and enterobacteriaceae bacteria. The Centers for Disease Control and Prevention warned the medical community in March of 2013 about their concern for a deadly GNB which is called carbapenem-resistant enterobacteriaceae. This potentially lethal bacterium spreads quickly in healthcare settings and typically kills half of all patients who contract it.
There is still a window of time for research and development teams to tackle this urgent cause. On March 25, 2013 Trius Therapeutics announced that their new second-generation antibiotic tedizolid phosphate is succeeding in clinical trials and looks very promising. The “Establish 2” trial proved in studies to be a comparable alternative to Pfizer’s Zyvox. With the patent for Zyvox expiring in 2015, researchers are upbeat about the positive study results from tedizolid. Patients in the Phase II trial were treated with both tedizolid and Zyvox for acute bacterial skin and skin structure infections with success, based on a once daily dosing of tedizolid. The ease of administration and possibility of a treatment for multi-drug resistant Staphylococcus aureus makes tedizolid an antibiotic to watch.
Continued research and development of medications to fight GNB is not only essential to human life, but it has also become increasingly urgent. LGM Pharma can provide Tedizolid Phosphate, CAS number 856867-55-5 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.